Endomucin Inhibitors

Common Endomucin Inhibitors include, but are not limited to Vatalanib Dihydrochloride CAS 212141-51-0, Sorafenib CAS 284461-73-0, Sunitinib, Free Base CAS 557795-19-4, Thalidomide CAS 50-35-1 and TNP 470 CAS 129298-91-5.

Endomucin is a glycoprotein prominently expressed on the endothelial cell surface, particularly in high endothelial venules. It plays a pivotal role in various cellular processes, including cell adhesion, migration, and the maintenance of vascular integrity. Endomucin acts primarily by modulating interactions between endothelial cells and other cells, such as leukocytes, thereby influencing various physiological processes, including inflammation and immune cell trafficking. This protein is characterized by its extensive O-glycosylation, which is believed to contribute to its functions, particularly its anti-adhesive properties.

Endomucin Inhibitors are a class of chemical compounds that can reduce or halt the activity, expression, or function of endomucin. These inhibitors may operate through a variety of mechanisms. Some might directly bind to endomucin, thereby altering its structure or preventing it from interacting with other proteins or cells. Others may interfere with the pathways responsible for the expression or post-translational modifications of endomucin. Yet another subset could disrupt the interactions between endomucin and its binding partners, thus impeding its functional roles. Given the significance of endomucin in maintaining vascular homeostasis and mediating cell-cell interactions, these inhibitors can provide invaluable tools for researchers aiming to elucidate the precise roles of endomucin in various physiological contexts. By modulating endomucin function, these compounds could offer insights into the intricate dynamics of endothelial cell behavior and their interactions with the surrounding cellular environment.